$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024
The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates in adults
NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.
